Stresscopin

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameStresscopin
Drug Alias NamePeptide infusion therapy - Renova TherapeuticsJNJ-39588146RT-400
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionCorticotropin-releasing factor receptor 2 stimulants
TargetsCorticotropin-releasing factor receptor 2
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumPolandRomania +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohnson & Johnson Pharmaceutical Research & Development LLC
Active IndicationsN/A
Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A